

## “Advances in Oncology Seminar series”

### *Miguel Ángel Piris*



*Director of Pathology Services,  
Hospital Universitario Marqués de Valdecilla  
& Scientific Director, IFIMAV  
Santander*

Title

“Cancer genomics, the basis for targeted  
therapy”

10<sup>th</sup> April 2014, 14.00h

**Biodonostia Health Research Institute**  
Donostia - San Sebastian

## MA Piris CV summary

Miguel Ángel Piris was born in Zaragoza (Spain) in 1952. He received his MD degree from the Universidad Complutense de Madrid in 1977 and his First Class Honours PhD degree from the Universidad Autónoma de Madrid in 1991. He was trained as a Pathologist at the Hospital Virgen de la Salud, Toledo, and the Fundación Jiménez Díaz in Madrid. In 1982 he carried out his advanced training at the Pathology Institute in the University of Kiel (Germany). He then moved to the John Radcliffe Hospital at the University of Oxford (UK) in 1989.

Piris is a Member of the WHO lymphoma/leukaemia panel, the International Lymphoma Study Group, Past-President of the European Association of Haemathology, and Head of the Spanish Network of Lymphoma Groups within the Spanish Cancer Group Network. From 2013, he is President of the Spanish Society of Pathology and Spanish Division of the International Pathology Academy (SEAP-IAP).

Until 2000 he served as Consultant and Chief of Section at the Pathology Department of the Complejo Hospitalario de Toledo, and was then appointed as Director of the CNIO's Molecular Pathology Programme and Leader of the CNIO Lymphoma Group. Since 2011, Dr. Piris is the Chief of Pathology in the Hospital Universitario Marqués de Valdecilla in Santander, and the scientific director of IFIMAV, as well as PI of the "Cancer Genomics" Research Group (<http://www.fmdv.org/Es/Unidades/Ifimav/AreasInvestigacion/Cancer/GenomicaCancer/Paginas/Miembros.aspx>).

He has contributed to over 250 articles published in international scientific journals of prestige. Most of his research has focused on lymphoid neoplasms, with numerous contributions to the classification, molecular pathogenesis and analysis of the alterations in the control of the cell cycle, transcriptional regulation and survival signaling.

## Advances in Oncology Seminar Series

La Comunidad Autónoma Vasca está realizando un indudable avance en Innovación e Investigación en todos los campos. En particular, la Provincia de Guipúzcoa está sentando las bases para ser un área de referencia en el área de la Oncología. Esto ha sido posible gracias a la inversión que los distintos Estamentos e Instituciones están realizando en este campo en los últimos años.

El Hospital Donostia, el Instituto de Investigación Sanitaria Biodonostia , la fundación Onkologikoa junto con la inestimable ayuda de la AECC Guipúzcoa consideran que es necesario seguir dando pasos adelante en el objetivo de ser un referente en investigación y para ello han organizado el Programa “**Advances in Oncology seminar series**”, una serie de seminarios que se realizará de manera mensual en la que va a participar lo más granado de la ciencia y medicina mundial en la lucha contra el cáncer. El objetivo es debatir los avances recientes y dirigir la investigación y tratamientos futuros que ha de realizarse en nuestra comunidad.